BAM
IPXL

Barrett Asset Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Barrett Asset Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-395
Closed -$13K – 413
2016
Q1 		$13K Buy
+395
New +$13.9K ﹤0.01% 307

Other funds holding IPXL

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Barrett Asset Management's IPXL Position: Q2 2016 in Review

Barrett Asset Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2016, closing a stake of 395 shares — an estimated $13K sold.

Barrett Asset Management first reported a position in IPXL in Q1 2016 and held it in 1 quarter. The position peaked at $13K in Q1 2016. 198 funds tracked by Wall St. Rank hold IPXL as of Q2 2016.

  • Barrett Asset Management reported no remaining Impax Laboratories, Inc. position as of Q2 2016 after selling out during the quarter.
  • Barrett Asset Management sold 395 Impax Laboratories, Inc. shares in Q2 2016, an estimated $13K.
  • Barrett Asset Management first reported a position in Impax Laboratories, Inc. in Q1 2016 and held it in 1 quarter.
  • Barrett Asset Management's Impax Laboratories, Inc. position peaked at $13K in Q1 2016.
  • 198 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2016.

Based on Barrett Asset Management's 13F filing for Q2 2016, filed 18 Jul 2016.